Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Accounts Payables (2017 - 2025)

Puma Biotechnology's Accounts Payables history spans 9 years, with the latest figure at $5.1 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 8.22% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $5.1 million, down 8.22%, while the annual FY2025 figure was $5.1 million, 8.22% down from the prior year.
  • Accounts Payables reached $5.1 million in Q4 2025 per PBYI's latest filing, down from $6.4 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $20.0 million in Q3 2021 to a low of $5.1 million in Q4 2025.
  • Average Accounts Payables over 5 years is $8.9 million, with a median of $7.7 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: crashed 66.09% in 2023, then surged 73.19% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $11.2 million in 2021, then tumbled by 42.37% to $6.4 million in 2022, then grew by 6.97% to $6.9 million in 2023, then decreased by 20.03% to $5.5 million in 2024, then decreased by 8.22% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Accounts Payables are $5.1 million (Q4 2025), $6.4 million (Q3 2025), and $5.4 million (Q2 2025).